Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;10(3):413-428.
doi: 10.1007/s40123-021-00354-1. Epub 2021 Jun 13.

A Review of Aflibercept Treatment for Macular Disease

Rodrigo Anguita  1 , Anastasia Tasiopoulou  1   2 , Syed Shahid  1 , Janice Roth  1 , Sing Yue Sim  1 , Praveen J Patel  3
Affiliations
Review

A Review of Aflibercept Treatment for Macular Disease

Rodrigo Anguita et al. Ophthalmol Ther. 2021 Sep.

Erratum in

Abstract

Aflibercept is a fully human recombinant fusion protein that includes the second domain of human VEGF receptor 1 and the third domain of human VEGF receptor 2. Despite the important role played by VEGF in maintaining the physiological condition of the retina under normal conditions, dysregulation of VEGF can result in pathological alterations including hyperpermeability of the retinal capillaries and migration and proliferation of retinal endothelial cells. Over the years, a number of studies have evaluated the use of intravitreal aflibercept in different retinal diseases. In this review, we aim to summarize the scientific evidence and recommendations for use of intravitreal aflibercept in neovascular age-related macular degeneration, diabetic macular oedema, macular oedema associated with retinal vein occlusion, and myopic choroidal neovascularization.

Keywords: Aflibercept; Diabetic macular oedema; Macular oedema associated with vein occlusion; Myopic choroidal neovascularization; Neovascular age-related macular degeneration; VEGF.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The recommended aflibercept treat-and-extend protocol by the UK panel of retinal experts for nAMD
Fig. 2
Fig. 2
The UK expert panel recommendations for DMO treatment with aflibercept
See this image and copyright information in PMC

References

    1. Eylea(aflibercept) injection, for intravitreal use [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals; 2019
    1. Regeneron announces FDA approval of EYLEA (aflibercept) injection for the treatment of wet age-related macular degeneration [press release]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2011.
    1. 3.Regeneron Pharmaceuticals Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 1) ClinicalTrials gov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2007[updated December 20, 2012]. http://clinicaltrials.gov/ct2/show/NCT00509795NLMidentifer:NCT00509795. Accessed 13 Nov 2012.
    1. 4.Bayer Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2) ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2008[updated February 27, 2012]. http://clinicaltrials.gov/ct2/show/NCT00637377NLMidentifer:NCT00637377. Accessed 13 Nov 2012.
    1. Congdon N, O’Colmain B, Klaver CC, et al. Eye Diseases Prevalence Research Group, Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–485. doi: 10.1001/archopht.122.4.477. - DOI - PubMed

LinkOut - more resources